Fluorine-18 clinical trials
How each study uses Fluorine-18 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Fluorine-18 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2020 | 1 |
| 2023 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 4
GE Healthcare (2) · Memorial Sloan Kettering Cancer Center (1) · Lantheus Biosciences Ltd. (1) · University of Calgary (1) · University of Cambridge (1) · Center Eugene Marquis (1)
Often tested with
Tested in the same studies.
D-fluoromethyltyrosine f-18 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Fluorine-18.
- Sep 2027A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)Phase 1 · Memorial Sloan Kettering Cancer Center
Studies
Open first, then newest update. How each study uses Fluorine-18 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Nuclear Imaging for Subtype Diagnosis of Primary AldosteronismRecruitingPhase 2University of CalgaryNCT05472493Written as [18-F]CETO
- PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With InflammationsCompletedPhase 1Lantheus Biosciences Ltd.NCT01089998Written as Fludeoxyglucose (18F)-IBA
- A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)Active, not recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT01697930Written as [18F] 4-L-Fluoroglutamine (2S,4R)
- Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast CancerWithdrawnPhase 1GE HealthcareNCT05634954Written as GEH121224 (18F) Injection
- Contribution of [18F]DPA-714 PET for Grading and Exploration of the Inflammatory Microenvironment of Glioma.WithdrawnNot applicableCenter Eugene MarquisNCT05672082Written as [18F]DPA-714
- CETO First in Human TrialStatus unknownNot applicableUniversity of CambridgeNCT04529018Written as [18F]CETO
- Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).CompletedPhase 1GE HealthcareNCT01738347Written as Arm 1 - GEH120714 (18F) Injection
Codes
What other systems call Fluorine-18 · ClinicalTrials.gg INT000634
- MeSH (NLM) C000615276Fluorine-18One source NLM
- UNII (FDA) GZ5I74KB8GFLUORINE F-18Confirmed NLM, Wikidata
- Wikidata Q2031969fluorine-18Confirmed NLM, Wikidata
- DrugBank DB13134One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000615276 | Fluorine-18 | One source NLM |
| UNII (FDA) | GZ5I74KB8G | FLUORINE F-18 | Confirmed NLM, Wikidata |
| Wikidata | Q2031969 | fluorine-18 | Confirmed NLM, Wikidata |
| DrugBank | DB13134 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.